Journal article
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Abstract
BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2.
METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either …
Authors
White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D
Journal
New England Journal of Medicine, Vol. 370, No. 18, pp. 1702–1711
Publisher
Massachusetts Medical Society
Publication Date
May 2014
DOI
10.1056/nejmoa1315878
ISSN
0028-4793